Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 711
  • Home
  • Print this page
  • Email this page


 
 Table of Contents  
REVIEW ARTICLE
Year : 2021  |  Volume : 7  |  Issue : 3  |  Page : 141-149

A literature survey on the biomarkers of cardiovascular disease


1 Department of Human Genetics and Molecular Biology, Medical Genetics and Epigenetics Laboratory, Bharathiar University, Coimbatore, Tamil Nadu, India
2 Department of Biotechnology, Bharathiar University, Coimbatore, Tamil Nadu, India

Date of Submission23-Jun-2020
Date of Acceptance15-Jan-2021
Date of Web Publication28-Sep-2021

Correspondence Address:
Dr. Arumugam Vijaya Anand
Department of Human Genetics and Molecular Biology, Medical Genetics and Epigenetics Laboratory, Bharathiar University, Coimbatore - 641 046, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/IJAM.IJAM_80_20

Rights and Permissions
  Abstract 


Biomarkers of any condition will help in predicting the disease that can help in improvised treatment and medication. Due to lack of symptoms and precursors, cardiovascular disease (CVD) is one of the leading reasons for death in population all over the world. To reduce the death rate and improve the therapeutic approach, biomarkers related to CVD can be helpful. The study of the levels of biomarkers in the body can help in predicting the chances of CVD. The literature study of biomarkers of CVD is to analyze the biomarkers and their role and levels in causing CVD. Among the various analyzed lipid-related markers like apolipoprotein B, apolipoprotein A1, lipoprotein (a), high-sensitivity cardiac troponin, high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, coronary artery calcification, cystatin C, it has been identified that the cystatin C is the biomarker for not only the chronic kidney disease but also a predictor of major CVD events.
The following core competencies are addressed in this article: Medical knowledge, Patient care, Systems-based practice.

Keywords: Biomarkers, cardiovascular disease, chronic kidney disease, cystatin C, therapeutics


How to cite this article:
Pavithra R, Sangeetha T, Velayuthaprabhu S, Anand AV. A literature survey on the biomarkers of cardiovascular disease. Int J Acad Med 2021;7:141-9

How to cite this URL:
Pavithra R, Sangeetha T, Velayuthaprabhu S, Anand AV. A literature survey on the biomarkers of cardiovascular disease. Int J Acad Med [serial online] 2021 [cited 2021 Dec 2];7:141-9. Available from: https://www.ijam-web.org/text.asp?2021/7/3/141/326820




  Introduction Top


Cardiovascular disease (CVD) refers to the condition that affects the heart or blood vessels.[1] CVD includes diseases like coronary artery disease, cerebrovascular disease, rheumatic heart disease, hypersensitive heart disease, etc., the risk of CVD may be increased by smoking, high blood pressure, high cholesterol, high glucose, unhealthy diet, lack of physical activity, and obesity.[2] CVD is the leading cause of global death in the past few years.[3],[4] According to the World Health Organization (WHO) report, 17.9 million people die each year from CVDs, which accounts for 31% of all deaths globally. In India, the age-adjusted CVD mortality rates are 349/1,00,000 in men and 265/1,00,000 in women.[5]


  Risk Stratification Top


The WHO reported that CVD is the source of great morbidity and mortality. The risk of developing CVD will increase with the number of risk factors nonheritable. Normally, the risk factors for CVD can be separated into nonmodifiable and modifiable risk factors.[6] Nonmodifiable risk factors are included age, gender, and case history. Many studies have shown that the prevalence of CVD will increase with age wherever every decade of life above the age of 40 years showed an increase in any vascular disease. The main modifiable risk factors are health conditions and lifestyle factors. The health conditions embrace high blood pressure, dyslipidemia, diabetes mellitus, and chronic kidney disease (CKD). A way of lifestyle factor includes cigarette, smoking, diet, exercise, obesity, and psychosocial factors. The main risk stratification as high blood pressure has an abundant quantity of evidence to support its role as a risk factor thinks about developing CVD.[7]


  Risk Factors of Cardiovascular Disease Top


The use of ancient cardiovascular risk factors emprises and predicts about one-half of future cardiovascular events.[8] The risk factors related to CVD are unit modifiable and nonmodifiable. The modifiable risk factors are physical inactivity, overwhelming tobacco, smoking, unhealthy diet, blood lipids, high blood pressure, and obesity. The WHO suggested that more than 60% of the global population is sufficiently inactive.[9] If the individual becomes physically inactive, the lifespan could decrease and will additionally pave the manner for the enhancement of any chronic health issues including any type of CVD.[5]

Tobacco smoking could be a leading reason for CVD morbidity and mortality.[10] The study prompt that tobacco may be considered the increasing risk issue of CVD area unit highest in current and up to date smokers, compared to never smokers and those who have quit in the more distant past. Tobacco smoking promotes CVD through damaging the epithelial tissue, increasing fatty deposits within the arteries, will increase coagulation, raises rarity compound protein low-density lipoprotein (LDL) steroid alcohol, and reduces high-density compound protein high-density lipoprotein (HDL) steroid alcohol. Some smokers possess a gene that increases the risk of CVD.[11] Women who smoke and additionally intake the alcohol increase the chance of CVD, heart condition, and stroke than men who smoke.[12] High blood pressure additionally will increase the risk of CVD. Patients with high blood pressure and diabetes with accompanied dyslipidemia are targets cardiovascular events.[13] The elevated levels of lipids within the blood area unit related to risk for CVD and stroke.[14]

Nonmodifiable risk factors are case history, overweight, and obesity.[15] Approximately two-thirds of adults are overweight or obese, and even modest excess body weight is related to a significantly increased risk of CVD connected mortality. Lifestyle interventions to promote weight loss reduce the chance of CVD related illness for patients to sustain over long periods of your time. The increased incidence of obesity has additionally contributed to important will increase within the prevalence of alternative vital CVD risk factors, including high blood pressure, dyslipidemia, endocrine resistance, and type 2 diabetes mellitus.[16]

Type 2 diabetes patients are being found to be more susceptible to CVD in comparison with healthy people.[17] Booth et al.[18] suggested that the individuals that suffer from physical inactivity and weight gain predisposes to CVD a lot of often within the people with spinal cord injury than within the general population. Another study has additionally suggested that the presence of high compound protein A, environmental and lifestyle factors, higher levels of insulin resistance, hyperinsulinemia, type 2 diabetes, impaired glucose tolerance, dyslipidemia, high blood pressure, obesity, low high-density compound protein levels characterized by the metabolic syndrome are another vital reason for increased CVD incidence in Indian population.[8]


  Biomarkers of Cardiovascular Disease Top


The discussed risk factors perform well to predict the risk of CVD but do not perfectly predict the future risk of CVD. Thus, the discovery of biomarkers associated with CVD risk has been done. Such markers include lipid-related markers as apolipoprotein A-1, apolipoprotein B-100, lipoprotein A, lipoprotein-associated phospholipase A2 (Lp-PLA2), natriuretic peptides (NP), high-sensitivity troponin T, high-sensitivity troponin I, high-sensitivity c-reactive protein (hs-CRP), coronary artery calcium, and Cystatin C.[3] These biomarkers have become important diagnostic tools to predict cardiovascular risk and are discussed below in this review and have been diagrammatically represented in [Figure 1].
Figure 1: Biomarkers of cardiovascular disease

Click here to view



  Lipid-Related Markers Top


Apolipoprotein B and apolipoprotein A1

Apolipoprotein B is the primary apolipoprotein of chylomicrons, very-LDL, intermediate-density lipoprotein, and LDL particles. The study suggests that the concentrations of apolipoprotein B have been found to be associated with heart disease and risk prediction of CVD.[19] Increased concentrations of HDL cholesterol have been closely associated with the decreased risk of future CVD. A study has suggested that the apolipoprotein A1 is the major protein component of HDL and it helps in predicting the risk of future CVD.

A study suggested that the lipid-related markers as apolipoprotein B and apolipoprotein A1 are structural and functional components of lipoprotein particles that serve as transporters of cholesterol. The ratio of apolipoprotein B and apolipoprotein A1 reflects the cholesterol transport and is shown strongly associated with the risk of CVD.[20] Many studies reported that apolipoprotein B/apolipoprotein A1 ratio is related to a CVD risk. Lu et al.[21] compared the samples of coronary heart disease (CHD) patients and healthy individuals who were overweight or obese to predict the risk of CVD. Based on the receiver operating characteristic curve analysis, it has resulted that the apolipoprotein B and apolipoprotein A1 ratio levels are associated in predicting the risk of CVD events that were overweight or obese.

Lipoprotein(a)

Malaguarnera et al.[22] have performed a study, which involved the determining of lipoprotein (a) values to predict the risk of cardiovascular events. Maranhão et al.[23] suggested that lipoprotein (a) can be considered as a genetic risk factor of CVD. The study has found that the lipoprotein (a) has been positively associated with CVD risk. Normally, lipoprotein (a) is a LDL particle bound to glycoprotein lipoprotein (a). They also suggest that lipoprotein (a) plays a role in the prothrombotic or antifibrinolytic effects or through accelerated atherogenesis and elevation in the levels of lipoprotein (a) is associated with increases in the risk of CVD.[24]

A study suggests that the lipoprotein (a) plays a critical role in the pro-inflammatory reaction as inhibition of the activation of plasminogen; inhibition of the activation of tumor growth factor-beta; activation of acute inflammation; induction of the expression of adhesion molecules; elevation of the production of cytokines are associated with risk of CVD events.[25] Another study has used a Mendelian randomization approach to predict the association of lipoprotein (a) with CVD. Based on the cross-sectional general population study in more than 29,000 individuals, the elevated lipoprotein (a) levels were associated with an increased risk of CVD events.[26]


  Lipoprotein-Associated Phospholipase A2 Top


A study indicates that the Lp-PLA2 is an associate accelerator secreted by the inflammatory cells that circulate and bind in the main to beta-lipoprotein that is taken into account as a marker for CVD risk. A study examined Lp-PLA2 and determined that the mass of Lp-PLA2 will increase related to the danger of major CVD events.[27] A study investigated the link between Lp-PLA2 and markers of CVD risk, and it has been measured that Lp-PLA2 was within the high CVD risk class and may be pictured as an early biomarker of CVD risk events.[28]

A study by Cook et al.[29] has prompt that Lp-PLA2 has the properties of proatherogenic-associated antiatherogenic role and analyzed that elevated levels of Lp-PLA2 are related to an enhanced risk of vessel events. Lp-PLA2 is the associate accelerator that conjointly exhibits unhealthy property which has been related to the danger of vessel events.[30]


  Natriuretic Peptides Top


The NPs, including brain-type natriuretic peptide (BNP) or N-terminal prohormone of BNP (NT-pro BNP), are biomarkers that are strongly associated with the risk of CVD events.[31] Several studies suggest that elevated BNP and NT-pro BNP levels increased the risk of total CVD, CHD, and stroke. In general populations, the levels of BNP and NT-pro BNP are higher in women than in men. Hence, the increase in BNP or NT-pro BNP may be used for the prediction of CVD risk.[32]

The NPs include three characterized hormones as atrial natriuretic peptide (ANP), BNP, and C-type NP which are mainly involved in cardiovascular events. Normally, ANP and BNP are synthesized mainly in the heart, and BNP is mainly produced by endothelial cells.[33] Due to natriuretic, antiproliferative, and antiapoptotic effects, they are involved in the pathogenic mechanisms leading to major CVD like heart failure, coronary artery disease, hypertension, and cerebrovascular accidents.[30]


  High-Sensitivity Cardiac Troponin Top


High-sensitivity cardiac troponin T, high-sensitivity cardiac troponin I has been used as a specific marker for diagnosis and risk stratification of CVD. When the levels are compared in the general population, the high-sensitivity cardiac troponin T and high-sensitivity cardiac troponin I levels are significantly higher in men than in women. A study by Welsh et al.[34] indicates that the elevations in high-sensitivity cardiac troponin T or high-sensitivity cardiac troponin I levels are strongly associated with the risk of CVD events. A study suggests that an increase in high-sensitivity cardiac troponin is associated with a higher risk of CVD. The high sensitivity cardiac troponin T has been found to be individually associated with the CVD events in a study conducted by Tehrani et al.[35]

A study has suggested that the elevated levels on the measurement of the cardiac troponin as cardiac troponin T and cardiac troponin I are associated with the risk of CVD events by comparing with normal healthy individuals.[36] Among the 19,501 individuals, the Scottish health study reveals that CVD risk events are strongly associated with cardiac troponin T and cardiac troponin I. They identified as five loci (53 individual single nucleotide polymorphisms (SNPs)) that had GWAS (genome-wide association study) in cardiac troponin I and a different set of four loci (SNPs) for cardiac troponin T noted as elevations of these are strongly associated with CVD events.[32]


  High-Sensitivity C-Reactive Protein Top


A study reported that hs-CRP is associated with CVD. CRP is mainly produced by the liver as an acute phase reactant and is strongly regulated by interleukin-6 concentrations. The blood concentrations of hs-CRP have been used to assess the risk of CVD, heart attack, and stroke as well as cholesterol levels. A study found that elevated levels of CRP were associated with three times the greater risk of CVD.[37] CRP may increase in CVD in response to infectious agents, including the inflammatory reactions in the coronary vessels. The circulating CRP levels were analyzed in the CVD patients and has been observed to be associated with CVD, with or without myocardial tissue damage.[38] The hs–CRP has been investigated extensively as a marker of inflammatory response that is useful in predicting the risk of CVD. The study described that the measurement of hs–CRP in CVD patients with diabetes and hypertension may prove to be an even better marker of risk response.[11]

A study by Wallace et al.[39] indicates that the CRP can be a screening tool for prediction of CVD. Based on the Framingham risk score, positive associations between elevated CRP levels and incident CVD has been observed. A case-cohort study assessed the association of CRP with incident CHD and suggested a positive association. Therefore, the basic risk factor model, which includes age, sex, total and HDL cholesterol levels, blood pressure, and elevated CRP levels, may predict the risk of CHD.[40] A study by and Joseph et al.[41] suggested the positive effects of atorvastatin on CRP and lipid profile in patients with stroke, as information on atorvastatin may predict the risk of cerebrovascular morbidity and mortality.


  Coronary Artery Calcification Top


A study indicated that coronary artery calcification (CAC) is a strong predictor of CVD risk events and mortality. CAC is a highly specific feature of coronary atherosclerosis. The concentration of CAC performed by computer tomography increases the levels of CAC are associated with the risk of CVD.[42] The studies performed by Orimoloye et al.[43] determine the risk of CVD events based on CAC scores. Among the study population of 6764 participants analyzed, the CAC scores positively correlate with the risk of CVD.[43]

The prospective cohort study indicates that the higher levels of CAC are strongly associated with risk factors of CVD, myocardial infarction, heart failure, all-cause mortality.[44] Among the study population of 1541 participants aged 35–60 years analyzed, the inclusion of CAC score for predicting CVD risk factors overall of all the above mentioned.[45] The study determines the relationship between CAC scores and cardiovascular events. Using the computer tomography to measure the CAC in 1205 participants and analyzed that increase the scores of CAC associated with an increase in the risk of cardiovascular events and mortality.[46],[47]


  Cystatin C Top


The Framingham heart study targeted a high range of proteins through the proteomic platform by separation, quantification, and characterization in the biological system using the two-dimensional electrophoresis.[48],[49]suggested that cystatin C biomarker has been associated with the incidence of CVD using multivariate Cox models. The normal concentration of serum cystatin C ranges from 0.6 to 1 mg/L.[50] The risk of CVD increases with the increase in cystatin C concentration.[51] Higher the concentration of protein increases the risk factors of CVD as age, sex, body mass index, LDL and HDL cholesterol, and smoking. Higher the level of cystatin C increases the risk of kidney function, hypertension, and dyslipidemia.[52]

The study investigated the cystatin C levels to predict ischemic stroke risk and CVD events. Based on the samples analyzed in China using cohort study and decision free model, the levels of cystatin C and risk of stroke resulted that the high levels of cystatin C are highly associated with risk of ischemic stroke and CVD events.[53] The study investigated the cystatin C for risk stratification in patients after an acute coronary syndrome by estimated glomerular filtration rate (eGFR), a strong correlation with creatinine and moderate correlation with fibroblast growth factor, and weak correlation with BNP. Studies have also shown that the higher concentration of cystatin C increases the risk of CVD and Heart failure.[54] Hence, cystatin C is found to be associated with CVD and its risk.

The biomarkers discussed so far in the current study have a notable role in other clinical condition diagnoses apart from CVD, and the same is shown in [Table 1].
Table 1: Various biomarkers and their uses in clinical conditions

Click here to view



  Diseases Involved in Cardiovascular Disease Top


A meta-analysis reported the major diseases which are strongly and directly related to cardiovascular mortality.[81] Dyslipidemia is shown to be independently associated with CVD through disturbances in the lipid metabolism as elevated with the levels of total cholesterol, LDL cholesterol, low HDL cholesterol. Diabetes mellitus is associated with CVD; equally, it is also associated with a similar risk of myocardial infarction.[82] Therefore CKD is also considered as commonly associated with increased in all-cause and cardiovascular mortality events through decreased glomerular filtration rate and increased proteinuria.[83]


  Selection Criteria and Importance of the Study Top


The current literature survey mainly focuses on the biomarkers related to the prediction of CVD, and the outline of the selection criteria followed for the study is shown in [Figure 2]. The current literature survey has been aimed at analyzing the various biomarkers, which has a notable role in the diagnosis of CVD. The identification of possible biomarkers for the diagnosis of an important clinical condition paves a significant way for the discovery of drugs and treatment of the condition at the earliest stage possible. The CVD is one of the fatal diseases that may be asymptomatic till a certain stage. The biomarkers considered for the study are very common molecules that have a diagnostic role in other clinical conditions simultaneously, and hence, the analysis of these biomarkers in comparison to CVD as well as another clinical condition seems to be an effective diagnostic process in case of significant positive results.
Figure 2: Selection criteria of current literature study

Click here to view



  Conclusion Top


Prediction of biomarkers associated with CVD helps to monitor and prevent the risks for CVD. The CVD biomarkers are used as diagnostic, prognostic, and predictive biomarkers. The biomarkers may also be the targets for drug delivery and development. Other than these biomarkers osteoprotegerin, neopterin, cardiotrophin, and glycoprotein are also used, which are associated with the risk of CVD events. Here, high-sensitivity cardiac troponin T and high-sensitivity cardiac troponin I is the specific inflammatory marker to predict the risk of myocardial injury. Then, the hs-CRP biomarker acts as a predictor of CVD events. Lp-PLA2, secretory phospholipase A2, and elevated levels of NP and galectin-3 predict the risk of cardiovascular events. The cystatin C has been identified as not only as a biomarker of CVD but also a predictor of major events in CKD.

From the observed analysis of available literature, the CVD can be predicted at the earlier stages using troponin T as a biomarker. Though other biomarkers have an efficient prediction of the clinical condition, troponin T plays its role as a chief. Although hs-CRP can also be considered a major biomarker, it can be found in other related inflammatory conditions too, and hence, this literature recommends the troponin T as chief and predominant indicators of CVD at its earliest stage, followed by the other biomarkers.

Acknowledgment

The authors acknowledge the institutional authorities and the laboratory fellows for rendering their help during the preparation of manuscripts.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Author Contributions

Ravindran Pavithra have designed the manuscript. Thangavelu Sangeetha reviewed and structured the manuscript. Shanmugam Velayuthaprabhu reviewed and edited the manuscript. Arumugam Vijaya Anand have corrected and finalised the manuscript. All the authors have contributed to the structuring and framing the concept of the manuscript.

Ethical conduct of research

The authors of this manuscript declare that this scientific work complies with reporting quality, formatting, and reproducibility guidelines set forth by the EQUATOR Network (http://www.equator-network.org). The authors also attest that because there was no clinical investigation carried out, the Institutional Review Board/Ethics Committee approval was not required.



 
  References Top

1.
Mendis S, Puska P, Norrving B. Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization in Collaboration with the World Heart Federation and the World Stroke Organization; 2011. p. 3-18.  Back to cited text no. 1
    
2.
Anand SS, Yusuf S, Jacobs R, Davis AD, Yi Q, Gerstein H, et al. Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: The Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). Lancet 2001;358:1147-53.  Back to cited text no. 2
    
3.
Huang Y, Gulshan K, Nguyen T, Wu Y. Biomarkers of cardiovascular disease. Dis Markers 2017;2017:8208609.  Back to cited text no. 3
    
4.
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 2006;367:1747-57.  Back to cited text no. 4
    
5.
World Health Organization. Burden: Mortality, morbidity and risk factors. In: Alwan A, editor. Global Status Report on Noncommunicable Diseases 2010. Geneva: World Health Organization; 2011.  Back to cited text no. 5
    
6.
Nangia R, Singh H, Kaur K. Prevalence of cardiovascular disease (CVD) risk factors. Med J Armed Forces India 2016;72:315-9.  Back to cited text no. 6
    
7.
Singh S, Zeltser R. Cardiac Risk Stratification. StatPearls. Treasure Island (FL): StatPearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507785/. [Last accessed on 2020 Feb 29].  Back to cited text no. 7
    
8.
Gupta S, Gudapati R, Gaurav K, Bhise M. Emerging risk factors for cardiovascular diseases: Indian context. Indian J Endocrinol Metab 2013;17:806-14.  Back to cited text no. 8
    
9.
Bauman A, Bull F, Chey T, Craig CL, Ainsworth BE, Sallis JF, et al. The International Prevalence Study on Physical Activity: Results from 20 countries. Int J Behav Nutr Phys Act 2009;6:21.  Back to cited text no. 9
    
10.
Banks E, Joshy G, Korda RJ, Stavreski B, Soga K, Egger S, et al. Tobacco smoking and risk of 36 cardiovascular disease subtypes: Fatal and non-fatal outcomes in a large prospective Australian study. BMC Med 2019;17:128.  Back to cited text no. 10
    
11.
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: A report from the American heart association. Circulation 2017;135:e146-603.  Back to cited text no. 11
    
12.
Paquissi FC, Manuel V, Manuel A, Mateus GL, David B, Béu G, et al. Prevalence of cardiovascular risk factors among workers at a private tertiary center in Angola. Vasc Health Risk Manag 2016;12:497-503.  Back to cited text no. 12
    
13.
Anand AV, Mundeep M, Divya N, Senthil R, Mohamed Mydeen Abdul Kapoor, Gowri J, Begum TN. Clinical significance of hypertension, diabetes and inflammation, as predictor of cardiovascular disease. Sci Direct 2011;2:369-73.  Back to cited text no. 13
    
14.
Tsimikas S. Lipoprotein (a): Novel target and emergence of novel therapies to lower cardiovascular disease risk. Curr Opin Endocrinol Diabetes Obes 2016;23:157-64.  Back to cited text no. 14
    
15.
Duncan S, Duncan EK, Fernandes RA, Buonani C, Bastos KD, Segatto AF, et al. Modifiable risk factors for overweight and obesity in children and adolescents from São Paulo, Brazil. BMC Public Health 2011;11:585.  Back to cited text no. 15
    
16.
Imes CC, Lewis FM. Family history of cardiovascular disease, perceived cardiovascular disease risk, and health-related behavior: A review of the literature. J Cardiovasc Nurs 2014;29:108-29.  Back to cited text no. 16
    
17.
Grigorescu ED, Lacatusu CM, Floria M, Mihai BM, Cretu I, Sorodoc L. Left ventricular diastolic dysfunction in type 2 diabetes-progress and perspectives. Diagnostics (Basel) 2019;9:121.  Back to cited text no. 17
    
18.
Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic diseases. Compr Physiol 2012;2:1143-211.  Back to cited text no. 18
    
19.
Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, et al. Apolipoprotein B particles and cardiovascular disease: A narrative review. JAMA Cardiol 2019;4:1287-95.  Back to cited text no. 19
    
20.
Tamang HK, Timilsina U, Singh KP, Shrestha S, Raman RK, Panta P, et al. Apo B/Apo A-I Ratio is Statistically A Better Predictor of Cardiovascular Disease (CVD) than Conventional Lipid Profile: A Study from Kathmandu Valley, Nepal. J Clin Diagn Res 2014;8:34-6.  Back to cited text no. 20
    
21.
Lu M, Lu Q, Zhang Y, Tian G. ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity. J Biomed Res 2011;25:266-73.  Back to cited text no. 21
    
22.
Malaguarnera M, Vacante M, Russo C, Malaguarnera G, Antic T, Malaguarnera L, et al. Lipoprotein(a) in cardiovascular diseases. Biomed Res Int 2013;2013:650989.  Back to cited text no. 22
    
23.
Maranhão RC, Carvalho PO, Strunz CC, Pileggi F. Lipoprotein (a): Structure, pathophysiology and clinical implications. Arq Bras Cardiol 2014;103:76-84.  Back to cited text no. 23
    
24.
Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J 2010;31:2844-53.  Back to cited text no. 24
    
25.
O'Donoghue ML, Morrow DA, Tsimikas S, Sloan S, Ren AF, Hoffman EB, et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol 2014;63:520-7.  Back to cited text no. 25
    
26.
Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301:2331-9.  Back to cited text no. 26
    
27.
Mirshad PV, Jithesh TK, Jaideep Mahendra, Prema Gurumurthy. Lipoprotein associated phospholipase A2 (Lp-Pla2) as an emerging cardiovascular marker. American Journal of Biochemistry 2017;7:47-53.  Back to cited text no. 27
    
28.
Ross Eckard A, Longenecker CT, Jiang Y, Debanne SM, Labbato D, Storer N, et al. Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection. HIV Med 2014;15:537-46.  Back to cited text no. 28
    
29.
Cook NR, Paynter NP, Manson JE, Manson JE, Martin LW, Robinson JG, et al. Clinical utility of lipoprotein-associated phospholipase A₂ for cardiovascular disease prediction in a multiethnic cohort of women. Clin Chem 2012;58:1352-63.  Back to cited text no. 29
    
30.
Younus A, Humayun C, Ahmad R, Ogunmoroti O, Kandimalla Y, Aziz M, et al. Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: A systematic review. J Clin Lipidol 2017;11:328-37.  Back to cited text no. 30
    
31.
Daniels LB. Natriuretic peptides and assessment of cardiovascular disease risk in asymptomatic persons. Curr Cardiovasc Risk Rep 2010;4:120-7.  Back to cited text no. 31
    
32.
Felker GM, Petersen JW, Mark DB. Natriuretic peptides in the diagnosis and management of heart failure. CMAJ 2006;175:611-7.  Back to cited text no. 32
    
33.
Cannone V, Cabassi A, Volpi R, Burnett JC, Jr. Atrial natriuretic peptide: a molecular target of novel therapeutic approaches to cardio-metabolic disease. Int J Mol Sci 2019;20:3265.  Back to cited text no. 33
    
34.
Welsh P, Preiss D, Hayward C, Shah ASV, McAllister D, Briggs A, et al. Cardiac troponin T and troponin I in the general population. Circulation 2019;139:2754-64.  Back to cited text no. 34
    
35.
Tehrani DM, Fan W, Nambi V, Gardin J, Hirsch CH, Amsterdam E, et al. Trends in blood pressure and high-sensitivity cardiac troponin-T with cardiovascular disease: The cardiovascular health study. Am J Hypertens 2019;32:1013-20.  Back to cited text no. 35
    
36.
Collinson P, Gaze D, Goodacre S. Comparison of contemporary troponin assays with the novel biomarkers, heart fatty acid binding protein and copeptin, for the early confirmation or exclusion of myocardial infarction in patients presenting to the emergency department with chest pain. Heart 2014;100:140-5.  Back to cited text no. 36
    
37.
Cozlea DL, Farcas DM, Nagy A, Keresztesi AA, Tifrea R, Cozlea L, et al. The impact of C reactive protein on global cardiovascular risk on patients with coronary artery disease. Curr Health Sci J 2013;39:225-31.  Back to cited text no. 37
    
38.
Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapy. Int J Cardiol 2013;168:5126-34.  Back to cited text no. 38
    
39.
Wallace ML, Ricco JA, Barrett B. Screening strategies for cardiovascular disease in asymptomatic adults. Prim Care 2014;41:371-97.  Back to cited text no. 39
    
40.
Fox ER, Samdarshi TE, Musani SK, Pencina MJ, Sung JH, Bertoni AG, et al. Development and validation of risk prediction models for cardiovascular events in black adults: The Jackson heart study cohort. JAMA Cardiol 2016;1:15-25.  Back to cited text no. 40
    
41.
Joseph J, Depp C, Martin AS, Daly RE, Glorioso DK, Palmer BW, et al. Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups. Schizophr Res 2015;168:456-60.  Back to cited text no. 41
    
42.
Thomas IC, Forbang NI, Criqui MH. The evolving view of coronary artery calcium and cardiovascular disease risk. Clin Cardiol 2018;41:144-50.  Back to cited text no. 42
    
43.
Orimoloye OA, Mirbolouk M, Uddin SMI, Dardari ZA, Miedema MD, Al-Mallah MH, et al. Association between self-rated health, coronary artery calcium scores, and atherosclerotic cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis (MESA). JAMA Netw Open 2019;2:e188023.  Back to cited text no. 43
    
44.
Chen J, Mohler ER 3rd, Garimella PS, Hamm LL, Xie D, Kimmel S, et al. Ankle brachial index and subsequent cardiovascular disease risk in patients with chronic kidney disease. J Am Heart Assoc 2016;5:e003339.  Back to cited text no. 44
    
45.
Wang XR, Zhang JJ, Xu XX, Wu YG. Prevalence of coronary artery calcification and its association with mortality, cardiovascular events in patients with chronic kidney disease: A systematic review and meta-analysis. Ren Fail 2019;41:244-56.  Back to cited text no. 45
    
46.
Chen J, Budoff MJ, Reilly MP, Yang W, Rosas SE, Rahman M, et al. Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease. JAMA Cardiol 2017;2:635-43.  Back to cited text no. 46
    
47.
Hom C, Luo Y, Budoff M. The effects of aged garliac extract on coronary artery calcification progression and blood pressure. J Nutr Food Sci 2015;S5:005.  Back to cited text no. 47
    
48.
Zivlas C, Triposkiadis F, Psarras S, Giamouzis G, Skoularigis I, Chryssanthopoulos S, et al. Cystatin C and galectin-3 as therapeutic targets in heart failure. Ther Adv Cardiovasc Dis 2018;12:233-5.  Back to cited text no. 48
    
49.
Shlipak MG, Coca SG, Wang Z, Devarajan P, Koyner JL, Patel UD, et al. Presurgical serum cystatin C and risk of acute kidney injury after cardiac surgery. Am J Kidney Dis 2011;58:366-73.  Back to cited text no. 49
    
50.
Villa P, Jiménez M, Soriano MC, Manzanares J, Casasnovas P. Serum cystatin C concentration as a marker of acute renal dysfunction in critically ill patients. Crit Care 2005;9:R139-43.  Back to cited text no. 50
    
51.
Van der Laan SW, Fall T, Soumare A, Teumer A, Sedaghat S, Baumert J, et al. Cystatin C and cardiovascular disease A mendelian randomization study. J Am Coll Cardiol 2016; 68:934-45.  Back to cited text no. 51
    
52.
Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 2009;75:652-60.  Back to cited text no. 52
    
53.
Wang YS, Ye J, Yang X, Zhang GP, Cao YH, Zhang R, et al. Association of retinol binding protein-4, cystatin C, homocysteine and high-sensitivity C-reactive protein levels in patients with newly diagnosed type 2 diabetes mellitus. Arch Med Sci 2019;15:1203-16.  Back to cited text no. 53
    
54.
Surendar J, Anuradha S, Ashley B, Balasubramanyam M, Aravindhan V, Rema M, et al. Cystatin C and cystatin glomerular filtration rate as markers of early renal disease in Asian Indian subjects with glucose intolerance (CURES-32). Metab Syndr Relat Disord 2009;7:419-25.  Back to cited text no. 54
    
55.
Ren L, Yi J, Li W, Zheng X, Liu J, Wang J, et al. Apolipoproteins and cancer. Cancer Med 2019;8:7032-43.  Back to cited text no. 55
    
56.
Kaneva AM, Potolitsyna NN, Bojko ER, Odland JØ. The apolipoprotein B/apolipoprotein A-I ratio as a potential marker of plasma atherogenicity. Dis Markers 2015;2015:591454.  Back to cited text no. 56
    
57.
Emamzadeh FN. Role of apolipoproteins and α-synuclein in Parkinson's disease. J Mol Neurosci 2017;62:344-55.  Back to cited text no. 57
    
58.
Elliott DA, Weickert CS, Garner B. Apolipoproteins in the brain: Implications for neurological and psychiatric disorders. Clin Lipidol 2010;51:555-73.  Back to cited text no. 58
    
59.
Zhan X, Chen Y, Yan C, Liu S, Deng L, Yang Y, et al. Apolipoprotein B/apolipoprotein A1 ratio and mortality among incident peritoneal dialysis patients. Lipids Health Dis 2018;17:117.  Back to cited text no. 59
    
60.
Upadhyay RK. Emerging risk biomarkers in cardiovascular diseases and disorders. J Lipids 2015;2015:971453.  Back to cited text no. 60
    
61.
Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-23.  Back to cited text no. 61
    
62.
Cojocaru M, Cojocaru IM, Silosi I. Lipoprotein-associated phospholipase A2 as a predictive biomarker of sub-clinical inflammation in cardiovascular diseases. Maedica (Bucur) 2010;5:51-5.  Back to cited text no. 62
    
63.
Sofogianni A, Alkagiet S, Tziomalos K. Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease. Curr Pharm Des 2018;24:291-6.  Back to cited text no. 63
    
64.
Gallagher J, Watson C, Campbell P, Ledwidge M, McDonald K. Natriuretic peptide-based screening and prevention of heart failure. Card Fail Rev 2017;3:83-5.  Back to cited text no. 64
    
65.
Volpe M, Rubattu S, Burnett J Jr., Natriuretic peptides in cardiovascular diseases: Current use and perspectives. Eur Heart J 2014;35:419-25.  Back to cited text no. 65
    
66.
Xu RY, Zhu XF, Yang Y, Ye P. High-sensitive cardiac troponin T. J Geriatr Cardiol 2013;10:102-9.  Back to cited text no. 66
    
67.
Adamson PD, Hunter A, Madsen DM, Shah ASV, McAllister DA, Pawade TA, et al. High-sensitivity cardiac troponin I and the diagnosis of coronary artery disease in patients with suspected angina pectoris. Circ Cardiovasc Qual Outcomes 2018;11:e004227.  Back to cited text no. 67
    
68.
Beatty AL, Ku IA, Christenson RH, DeFilippi CR, Schiller NB, Whooley MA. High-sensitivity cardiac troponin T levels and secondary events in outpatients with coronary heart disease from the Heart and Soul Study. JAMA Intern Med 2013;173:763-9.  Back to cited text no. 68
    
69.
Deodhar SD. C-reactive protein: The best laboratory indicator available for monitoring disease activity. Cleve Clin J Med 1989;56:126-30.  Back to cited text no. 69
    
70.
Ahmadi-Ahangar A. Predictive ability of C-reactive protein for stroke. Caspian J Intern Med 2016;7:151-2.  Back to cited text no. 70
    
71.
Al Aseri ZA, Habib SS, Marzouk A. Predictive value of high sensitivity C-reactive protein on progression to heart failure occurring after the first myocardial infarction. Vasc Health Risk Manag 2019;15:221-7.  Back to cited text no. 71
    
72.
Habib SS, A Al Masri A. Relationship of high sensitivity C-reactive protein with presence and severity of coronary artery disease. Pak J Med Sci 2013;29:1425-9.  Back to cited text no. 72
    
73.
Kamath DY, Xavier D, Sigamani A, Pais P. High sensitivity C-reactive protein (hsCRP) & cardiovascular disease: An Indian perspective. Indian J Med Res 2015;142:261-8.  Back to cited text no. 73
[PUBMED]  [Full text]  
74.
Mohammadpour AH, Nazemi S, Mashhadi F, Rezapour A, Afshar M, Afzalnia S, et al. Evaluation of NPP1 as a novel biomarker of coronary artery disease: A pilot study in human beings. Adv Pharm Bull 2018;8:489-93.  Back to cited text no. 74
    
75.
Chen J, Budoff MJ, Reilly MP, Yang W, Rosas SE, Rahman M, et al. Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease. JAMA Cardiol 2017;2:635-43.  Back to cited text no. 75
    
76.
Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 2011;22:147-55.  Back to cited text no. 76
    
77.
Kar S, Paglialunga S, Islam R. Cystatin C is a more reliable biomarker for determining eGFR to support drug development studies. J Clin Pharmacol 2018;58:1239-47.  Back to cited text no. 77
    
78.
Salgado JV, França AK, Cabral NA, Lages J, Ribeiro VS, Santos AM, et al. Cystatin C, kidney function, and cardiovascular risk factors in primary hypertension. Rev Assoc Med Bras (1992) 2013;59:21-7.  Back to cited text no. 78
    
79.
van der Laan SW, Fall T, Soumaré A, Teumer A, Sedaghat S, Baumert J, et al. Cystatin C and cardiovascular disease: A mendelian randomization study. J Am Coll Cardiol 2016;68:934-45.  Back to cited text no. 79
    
80.
Vigil A, Condés E, Vigil L, Gallar P, Oliet A, Ortega O, et al. Cystatin C as a predictor of mortality and cardiovascular events in a population with chronic kidney disease. Int J Nephrol 2014;2014:127943.  Back to cited text no. 80
    
81.
Laslett LJ, Alagona P Jr, Clark BA 3rd, Drozda JP Jr, Saldivar F, Wilson SR, et al. The worldwide environment of cardiovascular disease: Prevalence, diagnosis, therapy, and policy issues: A report from the American College of Cardiology. J Am Coll Cardiol 2012;60:S1-49.  Back to cited text no. 81
    
82.
Emberson JR, Bennett DA. Effect of alcohol on risk of coronary heart disease and stroke: Causality, bias, or a bit of both? Vasc Health Risk Manag 2006;2:239-49.  Back to cited text no. 82
    
83.
O'Seaghdha CM, Tin A, Yang Q, Katz R, Liu Y, Harris T, et al. Association of a cystatin C gene variant with cystatin C levels, CKD, and risk of incident cardiovascular disease and mortality. Am J Kidney Dis 2014;63:16-22.  Back to cited text no. 83
    


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Risk Stratification
Risk Factors of ...
Biomarkers of Ca...
Lipid-Related Ma...
Lipoprotein-Asso...
Natriuretic Peptides
High-Sensitivity...
High-Sensitivity...
Coronary Artery ...
Cystatin C
Diseases Involve...
Selection Criter...
Conclusion
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed657    
    Printed14    
    Emailed0    
    PDF Downloaded63    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]